Regenerative medicine is not a distant reality—it's a transformative force that's shaping the world of medicinal therapeutics today. At Two Labs, we’ve proudly guided manufacturers from the earliest stages of pre-clinical development through to the life-changing patient outcomes that follow. If you missed our latest insights on the current state of the cell and gene therapy pipeline, we've made it easy to catch up. Check out our comprehensive webinar recap that charts the progress and previews the breakthroughs on the horizon. Start with the blog here and access the full webinar within for a full recap of where the pipeline stands. https://bit.ly/48wftyD
Two Labs ’s Post
More Relevant Posts
-
Complement drug discovery is booming, and Svar is at the forefront with functional cell-based and immunoassay, and biomarker assays. Join us for the ultimate hub of scientific advancements, where we'll talk about the role of complement in AAV gene therapy, along with new poster for our cell-based anaphylatoxin assessment. Don't forget to connect with our scientific experts to discover customizable Complement System solutions for your project! If you're too busy during the event, you can always contact us here: https://hubs.ly/Q02BRTmB0 #ComplementSystem #ComplementBiology #DrugDevelopment #ComplementingLifeScience #AnswesInLifeScience
-
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
-
Attended a webinar on The State of Cell and Gene Therapy today - it was a truly informative and insightful experience! Having recently completed a module on Biologics and Advanced Therapies led by none other than Prof. Bams Abila, MD, PhD, FFPM, the information presented made even more sense. Attending webinars like this provides a plethora of knowledge and helps in the holistic development of one's career. #lifelonglearning #professionaldevelopment
-
-
Day 2 of the Keystone Symposia Targeting Dry Age-Related Macular Degeneration: Pathophysiology and Emerging Therapies conference. Meet with or DM the Entos Pharmaceuticals team, Jason Ding, FCPA, FCA, Ping Wee, and Jailal Ablack attending the conference. Don't miss this poster! Poster Session 2, September 19, 7:30 to 9 pm Presenter: Ping Wee Title: Optimizing Ocular Gene Therapy: Harnessing the Potential of the Proteolipid Vehicle Nucleic Acid Delivery Platform #Fusogenix #PLV #genetherapy #ocular
-
-
Vice President - Program Lead I Organisational transformation I Digital transformation I Partnership evolution I Strategy development and implementation I Digital hub builder
#Gene and #cell-based therapies have the potential to provide targeted and personalized treatments, according to Charité - Universitätsmedizin Berlin and Bayer. They are a beacon of hope for people for whom conventional therapies have failed or for whom there is no treatment so far. With Charité and Bayer, two partners for major medical progress are coming together who will establish a new center for gene and cell therapy in #Berlin, which is to be established in 2025. More information in first comment #healthforall #teambayer
-
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)
-
Cell & Gene Therapy 🧬 Skills & Training | Business Development | #CommunityBuilding 🔊 Let’s connect✔️
🌍 🌎 🌏 Cell and Gene Therapy (CGT) landscape 📈 "With complexity and risk associated with each stage of assay development, our Advanced Therapy Medicinal Products (ATMP) best practice guidance offers a practical and phase-appropriate validation tool to help your cell and gene therapy programme succeed. Our ATMP guidance includes: - Application of Flow Cytometry - Vector Copy Number - Characterisation of the Capsid Particle Population for rAAV products - T Cell and NK Cell Characterisation Assays" Exciting publication from Medicines and Healthcare products Regulatory Agency. Jacqueline Barry leads on some really exciting work 🔊 This particularly vindicates the continued importance of developing a talented workforce. Flow Cytometry, qPCR / ddPCR and ELISA are some of the key pieces of equipment for the above assays 🥇 Ideas or requirements for training anyone? 😎 Cell and Gene Therapy Catapult, Ryan Smith, #regulatory, #assays, #skills, #communitybuilding
The British Pharmacopoeia recently launched new Advanced Therapy Medicinal Products (ATMP) best practice guidance for T Cell and NK Cell Characterisation Assays 🆕 The guidance is phase appropriate, trusted, and practical. Developed and approved by the British Pharmacopoeia (BP), in partnership with experts from the cell and gene therapy community including industry, NHS and academia ✅ Find out more 👉 https://bit.ly/3JaFrNi
-
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)
-
If you're curious how Theragent can support your cell therapy development, check out Brian Newsom's presentation on our latest capabilities and capacities. Thank you to Outsourced Pharma for hosting a great session! If you have any questions, send us a message to learn more about how Theragent can partner on your cell therapy at any stage. #CDMO #CGT #Manufacturing
Theragent Inc's Brian Newsom wraps an informative presentation in today's Outsourced Pharma Cell & Gene Therapy Capacity Update. If you missed it, you can still view the company's current capabilities and available capacities on-demand here: https://lnkd.in/d44CiVD8
-
-
Check out our latest publication about X-linked retinoschisis. Convincing regulators, such as the FDA and EMA, of the efficacy of gene therapy in IRDs and establishing feasible structural and functional endpoints for clinical trials, rely heavily on natural history trials. Looking forward to the LIGHTHOUSE study by Atsena Therapeutics, which uses a laterally spreading vector to achieve therapeutic levels of gene expression in the photoreceptors of the central retina, while avoiding the surgical risks of foveal detachment.
